Sort By

Citations & References

Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

  • Authors: Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW,
  • Journal: Clin Cancer Res (2007) 13:5745-5755
  • PubMed ID: 17908964
Catalog #

Citations & References

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

  • Authors: Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW,
  • Journal: BMC Med (2009) 7:77-77
  • PubMed ID: 20003408
Catalog #
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.

  • Authors: Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF, Donnelly JB, Glaser KB,
  • Journal: J Biol Chem (2011) 286:43951-43958
  • PubMed ID: 22020937
Catalog #

Citations & References

Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.

  • Authors: Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, Bahar I, Stephenson CR, Wipf P, Lazo JS,
  • Journal: Mol Pharmacol (2004) 66:824-833
  • PubMed ID: 15231869
Catalog #
  • N01X1SHTLAS
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)
  • ASN000020

Citations & References

PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.

  • Authors: Achiwa H, Lazo JS,
  • Journal: Cancer Res (2007) 67:643-650
  • PubMed ID: 17234774
Catalog #
  • N01X1SHTLAS
  • R415
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

Purified human pancreatic duct cell culture conditions defined by serum-free high-content growth factor screening.

  • Authors: Hoesli CA, Johnson JD, Piret JM,
  • Journal: PLoS One (2012) 7:e33999-e33999
  • PubMed ID: 22442738
Catalog #

Citations & References

Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system.

  • Authors: Ding GJ, Fischer PA, Boltz RC, Schmidt JA, Colaianne JJ, Gough A, Rubin RA, Miller DK,
  • Journal: J Biol Chem (1998) 273:28897-28905
  • PubMed ID: 9786892
Catalog #
  • H1399
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

Mgat5 and Pten interact to regulate cell growth and polarity.

  • Authors: Cheung P, Dennis JW,
  • Journal: Glycobiology (2007) 17:767-773
  • PubMed ID: 17400585
Catalog #
  • H1399
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

Multiple roles for the receptor tyrosine kinase axl in tumor formation.

  • Authors: Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB,
  • Journal: Cancer Res (2005) 65:9294-9303
  • PubMed ID: 16230391
Catalog #
  • N01X1SHTLAS
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)
  • ASN000020

Citations & References

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

  • Authors: Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S, Berquin IM, Pelech S, Hieter P, Maxwell C, Dunn SE,
  • Journal: Oncogene (2011) 30:3649-3660
  • PubMed ID: 21423216
Catalog #
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.

  • Authors: Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, Kang JS, Barry ST,
  • Journal: Mol Cancer Ther (2011) 10:770-783
  • PubMed ID: 21388971
Catalog #

Citations & References

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

  • Authors: Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M,
  • Journal: Cancer Res (2010) 70:288-298
  • PubMed ID: 20028854
Catalog #
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

  • Authors: Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST,
  • Journal: Mol Cancer Ther (2011) 10:861-873
  • PubMed ID: 21441409
Catalog #
  • N01X1SHTLAS
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)
  • ASN000020

Citations & References

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  • Authors: Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C,
  • Journal: Cancer Res (2006) 66:11851-11858
  • PubMed ID: 17178882
Catalog #
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)

Citations & References

A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

  • Authors: Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Bagherazadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S,
  • Journal: Mol Cancer Ther (2010) 9:1136-1146
  • PubMed ID: 20442301
Catalog #
  • N01X1SHTLAS
  • ASN00002P(Discontinued)
  • ASN00003L(Discontinued)
  • ASN0000S1(Discontinued)